Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453500 | 1.00 | LARS1 (1.00) | LARS1 | |
| Hydrochloric Acid SCHEMBL2679371 | 0.99 | LARS1 (0.97) | LARS1 | |
| Hydrochloric Acid SCHEMBL2679368 | 0.99 | LARS1 (0.97) | LARS1 | |
| Trifluoroacetic Acid SCHEMBL460911 | 0.90 | LARS1 (0.81) | LARS1 | |
| SCHEMBL19017152 | 0.86 | LARS1 (1.00) | LARS1 | |
| SCHEMBL18023954 | 0.86 | LARS1 (0.75) | LARS1 | |
| SCHEMBL18023945 | 0.86 | LARS1 (0.75) | LARS1 | |
| SCHEMBL5019539 | 0.85 | LARS1 (0.74) | LARS1 | |
| SCHEMBL18023971 | 0.85 | LARS1 (0.74) | LARS1 | |
| SCHEMBL18023942 | 0.85 | LARS1 (0.74) | LARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251678-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11008345-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008345-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| CN-108610356-B | Benzoxaborole derivatives for the treatment of bacterial infections | 阿纳科制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| EP-3251678-A1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Anacor Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9751898-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751898-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2613788-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012033858-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008345-B2 | Boron-containing small molecules | BCL6B, BTD, BROX | LARS1 2597/4885 |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | LARS1 2597/4885 |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | LARS1 2597/4885 |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | LARS1 2597/4885 |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | LARS1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.